Dernière nouvelles - Ypsomed

Ypsomed is driving the digitisation of its portfolio

31/01/2018 - 07:00 Press Releases Ypsomed Group

Burgdorf – Ypsomed continues to expand its offers for digital diabetes therapy with the launch of the mylife^™ App. The mylife^™ App is connected to the mylife^™ YpsoPump^® insulin pump via Bluetooth^® and continuously records current therapy data. Digital therapy solutions add to customer benefit and increase the success of therapy long-term.

En savoir plus... Ypsomed is driving the digitisation of its portfolio

Ypsomed grows during first half-year and raises its forecast for the year

09/11/2017 - 07:00 Press Releases Ypsomed Group

Burgdorf - During the first six months of the business year 2017/18, Ypsomed generated a consolidated total turnover of CHF 213.4 million. The growth corresponds to an increase in turnover of 15.1% (previous year: CHF 185.4 million). The net profit for the reporting period amounts to CHF 23.4 million (previous year CHF 22.4 million). The operating result amounts to CHF 26.9 million with an EBIT margin of 12.9 %. Ypsomed expects a growth in turnover of approximately 18% versus the presently forecast 15% and increases the forecast to an operating result of around CHF 60 million for the business year 2017/18.

En savoir plus... Ypsomed grows during first half-year and raises its forecast for the year

Ypsomed supplies Bigfoot Biomedical with infusion sets

24/10/2017 - 07:00 Press Releases Ypsomed Group

Burgdorf – Ypsomed and the US Bigfoot Biomedical company today announced their agreement for a partnership. Ypsomed will supply Bigfoot Biomedical with a modified, patented version of the Orbit infusion set. This will be used by Bigfoot in their clinical study on automated insulin therapy in people with diabetes.

En savoir plus... Ypsomed supplies Bigfoot Biomedical with infusion sets

Ypsomed opens up new markets

10/10/2017 - 07:00 Press Releases Ypsomed Group

Burgdorf – Following the successful launch of its own insulin pump, the mylife YpsoPump, Ypsomed pursues its continued growth and invests in establishing new subsidiaries throughout Europe. At the same time, the mylife YpsoPump is being launched in further European countries.

En savoir plus... Ypsomed opens up new markets

Ypsomed signs master agreement for range of injection systems

28/09/2017 - 16:12 Press Releases Ypsomed Group

Burgdorf – Hanmi Pharmaceutical Co., Ltd. has three biotechnology proteins in its project portfolio that are in various stages of development and approval.

En savoir plus... Ypsomed signs master agreement for range of injection systems

Communiqués

Ypsomed is driving the digitisation of its portfolio

Ypsomed grows during first half-year and raises its forecast for the year

Ypsomed supplies Bigfoot Biomedical with infusion sets

Ypsomed opens up new markets

Ypsomed signs master agreement for range of injection systems

Thomas Kutt